Gastroenteritis, commonly known as the "stomach flu," is an inflammation of the stomach and intestines that causes symptoms like diarrhea, vomiting, and abdominal pain. It is a very common condition that can affect people of all ages. While it is often caused by viruses like norovirus and rotavirus, it can also be triggered by bacteria, parasites, or even certain chemicals in contaminated food or water. For most healthy individuals, the illness is self-limiting and clears up within a few days with rest and rehydration. However, for infants, the elderly, and those with weakened immune systems, it can lead to severe dehydration and requires medical attention.
Market Analysis: The market for treating and preventing gastroenteritis is a significant part of the broader infectious disease market, with a specific focus on hydration products, diagnostics, and therapeutics. In 2025, the global oral rehydration solutions (ORS) market alone is valued at approximately $2.5 billion. The broader infectious disease therapeutics market, which includes treatments for severe cases of gastroenteritis, is valued at about $72.5 billion. This market is projected to reach approximately $101 billion by 2030, with a compound annual growth rate (CAGR) of 6.9%. This growth is driven by the high global incidence of gastroenteritis, increasing awareness of proper hydration and sanitation, and the continuous development of new diagnostic tests that can quickly identify the specific pathogen causing the infection. While North America and Europe hold a large share of the market, the Asia-Pacific region is expected to experience the fastest growth due to its large population and a rising focus on public health.
